share_log

CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025

CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025

CNS Pharmaceuticals | 8-K:CNS Pharmicals公布2024年第一季度财务业绩评估伯鲁比辛的潜在关键GBM研究已完成注册;Topline数据预计将于2025年上半年发布
美股SEC公告 ·  05/16 11:01
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息